Evidence map›Paper›PMID 28158314›Full record

ArticlePloS one2017

Identifying radiation-induced survivorship syndromes affecting bowel health in a cohort of gynecological cancer survivors.

Gunnar Steineck, Viktor Skokic, Fei Sjöberg, Cecilia Bull, Eleftheria Alevronta, Gail Dunberger, Karin Bergmark, Ulrica Wilderäng, Jung Hun Oh, Joseph O Deasy and 1 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03961217 completednot on this map

Return to Work Among Cancer Survivors With Treatment-induced Survivorship Syndromes

Typeobservational_patient_registrySponsorSahlgrenska University HospitalRan1991 to 2016Enrolled2,135ConditionsGynecologic Cancer, Prostate Cancer, Radiation Toxicity, MalignancyArmsRadiotherapy
NCT04534075 phase3completednot on this mapstarted 2020, after this paper: background citation

Dietary Fiber During Radiotherapy and Intestinal Inflammation - a Placebo-controlled Randomized Trial (FIDURA)

TypeinterventionalSponsorSahlgrenska University HospitalRan2020 to 2024Enrolled354ConditionsMalignant Neoplasm, Malignant Neoplasm of Rectum, Malignant Neoplasm of Anus, Malignant Neoplasm of Urinary BladderArmsCapsules containing either dietary fiber or placebo
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Gunnar SteineckDivision of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Viktor SkokicDivision of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Fei SjöbergDivision of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0000-0002-8305-7648
Cecilia BullDivision of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Eleftheria AlevrontaDivision of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Gail DunbergerInstitute of caring Sciences, Ersta Sköndal University College, Stockholm, Sweden.
Karin BergmarkDivision of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Ulrica WilderängDivision of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Jung Hun OhDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, United States of America.
Joseph O DeasyDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, United States of America.
Rebecka JörnstenChalmers University of Technology, Gothenburg, Sweden.
University of Gothenburg · SEMemorial Sloan Kettering Cancer Center · USChalmers University of Technology · SEKarolinska Institutet · SEMarie Cederschiöld University · SE

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundDuring radiotherapy unwanted radiation to normal tissue surrounding the tumor triggers survivorship diseases; we lack a nosology for radiation-induced survivorship diseases that decrease bowel health and we do not know which symptoms are related to which diseases.

methodsGynecological-cancer survivors were followed-up two to 15 years after having undergone radiotherapy; they reported in a postal questionnaire the frequency of 28 different symptoms related to bowel health. Population-based controls gave the same information. With a modified factor analysis, we determined the optimal number of factors, factor loadings for each symptom, factor-specific factor-loading cutoffs and factor scores.

resultsAltogether data from 623 survivors and 344 population-based controls were analyzed. Six factors best explain the correlation structure of the symptoms; for five of these a statistically significant difference (P< 0.001, Mann-Whitney U test) was found between survivors and controls concerning factor score quantiles. Taken together these five factors explain 42 percent of the variance of the symptoms. We interpreted these five factors as radiation-induced syndromes that may reflect distinct survivorship diseases. We obtained the following frequencies, defined as survivors having a factor loading above the 95 percent percentile of the controls, urgency syndrome (190 of 623, 30 percent), leakage syndrome (164 of 623, 26 percent), excessive gas discharge (93 of 623, 15 percent), excessive mucus discharge (102 of 623, 16 percent) and blood discharge (63 of 623, 10 percent).

conclusionLate effects of radiotherapy include five syndromes affecting bowel health; studying them and identifying the underlying survivorship diseases, instead of the approximately 30 long-term symptoms they produce, will simplify the search for prevention, alleviation and elimination.

Indexed as

AgedAged, 80 and overFemaleGenital Neoplasms, FemaleHumansMiddle AgedQuality of LifeRadiation InjuriesRadiotherapySurveys and Questionnaires

Identifiers

PMID28158314
PMCPMC5291512
OpenAlexW2585077397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.